Preliminary Select Third Quarter 2024 Results
- Revenue of approximately $151.7 million for the third quarter ended September 30, 2024, representing an approximate 1% decrease from the corresponding prior year period.
- Preliminary revenue by source for the third quarter is expected to be as follows:
- Instruments revenue of approximately $19.1 million, representing a 46% decrease from the corresponding prior year period. Instruments revenue consists of approximately $7.6 million of Chromium instruments revenue and $11.4 million of Spatial instruments revenue.
- Consumables revenue of approximately $126.2 million, representing 10% growth over the corresponding prior year period. Consumables revenue consists of approximately $96.5 million of Chromium consumables revenue and $29.7 million of Spatial consumables revenue.
- Services revenue of approximately $6.4 million, representing 48% growth over the corresponding prior year period.
- Preliminary revenue by geography for the third quarter is expected to be as follows:
- Americas revenue of approximately $87.8 million, an 11% decrease from the prior year period.
- EMEA revenue of approximately $37.9 million, an 18% increase over the prior year period.
- APAC revenue of approximately $26.0 million, a 15% increase over the prior year period.
- Cash and cash equivalents of approximately $398 million as of September 30, 2024.
"Third quarter revenue fell short of our expectations," said Serge Saxonov, Co-founder and CEO of 10x Genomics. "The previously announced modifications we made to our commercial processes and organization to increase effectiveness represented a significant change in how we engage with customers. The transition was more disruptive than we anticipated, especially in the Americas. At the same time, our customers continue to be cautious with their spending, particularly around capital purchases, which notably impacted instrument sales during the quarter. Despite these near-term headwinds, we are confident in the opportunity ahead and believe the steps we are taking will enable us to reach more customers, execute consistently across the portfolio and drive the broad democratization of our technologies."
初步精選 2024 年第三季度業績
- 截至2024年9月30日的第三季度收入約爲1.517億美元,比上年同期下降了約1%。
- 第三季度按來源分列的初步收入預計如下:
- 儀器收入約爲1,910萬美元,比上年同期下降了46%。儀器收入包括大約760萬美元的Chromium儀器收入和1140萬美元的空間儀器收入。
- 消耗品收入約爲1.262億美元,比上年同期增長10%。消耗品收入包括大約9,650萬美元的Chromium消耗品收入和2970萬美元的空間消耗品收入。
- 服務收入約爲640萬美元,比上年同期增長48%。
- 第三季度按地域劃分的初步收入預計如下:
- 美洲收入約爲8,780萬美元,比上年同期下降11%。
- 歐洲、中東和非洲的收入約爲3,790萬美元,比上年同期增長18%。
- 亞太地區收入約爲2600萬美元,比上年同期增長15%。
- 截至2024年9月30日,現金及現金等價物約爲3.98億美元。
10x Genomics聯合創始人兼首席執行官塞爾吉·薩克森諾夫表示:「第三季度收入低於我們的預期。」「我們先前宣佈的爲提高效率而對商業流程和組織進行了修改,這代表了我們與客戶互動方式的重大變化。這種轉型比我們預期的更具破壞性,尤其是在美洲。同時,我們的客戶繼續謹慎對待支出,特別是在資本購買方面,這明顯影響了本季度的儀器銷售。儘管存在這些短期的不利因素,但我們對未來的機遇充滿信心,並相信我們正在採取的措施將使我們能夠吸引更多客戶,在整個產品組合中保持一致的執行並推動我們技術的廣泛民主化。」